Ruth Plummer is Professor of Experimental Cancer Medicine in the Translational and Clinical Research Institute, Newcastle University and an honorary consultant medical oncologist in Newcastle Hospitals NHS Foundation Trust. She is Director of the Sir Bobby Robson Cancer Trials Research Centre within the Northern Centre for Cancer Care, which is a dedicated early phase clinical trials unit based within the regional cancer centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre. She is deputy director of the Newcastle University Centre for Cancer.
Ruth trained at Cambridge and Oxford Universities obtaining both a medical degree and science PhD before moving back home to Newcastle and settling with her family in Northumberland. Her research interests are in the field of DNA repair and early phase clinical trials of novel agents, taking the first in class PARP inhibitor into the clinic in 2003, ATR inhibitor in 2012 and MCT1 inhibitor in 2014.
Nationally she chaired the Cancer Research UK New Agents Committee 2012-2019, and is as a member of CRUK Clinical Research Committee. She is also a member of the MRC Precision Medicine Group, NIHR EME Board, NCRI Strategy Advisory Group and was elected to a Fellow of the Academy of Medical Sciences in 2018.